Rani Therapeutics Holdings, Inc. 2025 Annual Report: Key Highlights & Investor Insights

Executive Summary

Rani Therapeutics Holdings, Inc. has released its 10-K annual report for the fiscal year ending December 31, 2025. This report contains several important developments that investors and shareholders should closely examine, as they may impact the company’s share value and future direction.

Key Financial Highlights

• Public Float: As of June 30, 2025, the aggregate market value of Rani’s voting and non-voting common equity held by non-affiliates was approximately \$65 million, based on a closing price of \$0.51 per share.
• Shares Outstanding: As of February 28, 2026, the company had 99,721,927 shares of Class A common stock and 23,970,359 shares of Class B common stock outstanding. Notably, there are no shares of Class C common stock outstanding. Holders of Rani LLC units (subsidiary) who do not hold Class B stock can exchange their units for 1,124,194 shares of Class A common stock.
• Nasdaq Listing: The company’s Class A common stock (Symbol: RANI) remains listed on the Nasdaq Stock Market LLC.

Capital Raising & Recent Transactions

• July 2025 Securities Purchase Agreement: Rani entered into an agreement with an institutional investor resulting in the issuance and sale of 4,354,000 shares of Class A common stock and pre-funded warrants for 3,146,000 shares. Pre-funded warrants were exercisable immediately, at an exercise price of \$0.0001 per share, and the offering price was \$0.40 per share or \$0.3999 per warrant. The gross proceeds totaled \$3.0 million. All pre-funded warrants were fully exercised post-closing.
• May 2025 Letter Agreement: An existing institutional investor exercised for cash all outstanding Series B and Series C warrants. This confirms strong investor confidence but also potentially increases dilution.

Corporate Structure and Shareholder Rights

• Rani is a holding company, with its principal asset being its interest in Rani LLC. The company depends on distributions from LLC for taxes, expenses, and dividends. These distributions may be subject to limitations and restrictions, which could affect cash flow and dividend policy.
• Rani LLC may make distributions of cash to Rani Holdings in excess of what is needed for expenses and dividends. If these excess funds are not distributed as dividends, holders of LLC units could benefit from value appreciation upon exchanging their units for Class A common stock.

Internal Controls and Financial Reporting

• Material Weakness Identified: The company has identified a material weakness in its internal control over financial reporting. There is a risk that additional material weaknesses may arise in the future or that effective internal controls may not be maintained. This could result in material misstatements or failures to meet periodic reporting obligations, potentially impacting investor confidence and share price.
• Sarbanes-Oxley Compliance: Rani has not filed a report on internal controls attestation under Section 404(b) of the Sarbanes-Oxley Act, which is common for emerging growth and smaller reporting companies.

Nasdaq Listing and Potential Risks

• Rani notes the risk of failing to meet Nasdaq listing standards, which could lead to delisting. Delisting would materially impact the liquidity and value of shares.

Ownership and Voting Control

• Principal shareholders and management own a significant percentage of the equity and retain substantial control over corporate decisions. This concentration of ownership may prevent other shareholders from influencing key matters.

Intellectual Property Portfolio

• The company’s commercial success is partly dependent on building and maintaining a strong intellectual property portfolio, which is crucial for protecting technology and product candidates.

Forward-Looking Statements and Risks

• Rani’s future outlook includes uncertainties regarding expense estimates, capital requirements, regulatory approvals, clinical trial progress, commercialization plans, and the sufficiency of cash reserves.
• Management warns that forward-looking statements are subject to risks, uncertainties, and assumptions, including those described in the “Risk Factors” section. Investors are cautioned against relying solely on these statements for investment decisions.

Summary of Principal Risks

• Dependence on Rani LLC distributions.
• Potential dilution from warrant exercises and share exchanges.
• Material weaknesses in internal controls.
• Risk of Nasdaq delisting.
• Concentrated ownership and voting power.
• Uncertainties around intellectual property protection.

Conclusion

The 2025 Annual Report reveals a company at a pivotal stage, with active capital raising, material weaknesses in financial controls, and continued reliance on its Nasdaq listing. While institutional investors have shown confidence through recent transactions, shareholders must remain alert to risks such as dilution, internal control deficiencies, and potential delisting. These factors are material and could significantly affect Rani’s share value and investment profile.

Disclaimer: This article is a summary of Rani Therapeutics Holdings, Inc.’s 2025 Annual Report and is intended for informational purposes only. It does not constitute investment advice. Investors should conduct their own research and consult professional advisors before making any investment decisions. The company’s forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from those projected.

View Rani Therapeutics Holdings, Inc. Historical chart here